Pharma Q3 Preview | Lukewarm growth expected as US market sales slowdown The sector will also be affected by a high base of the year-ago quarter with its impact being felt acutely on the operating performance of drugmakers as analysts expect EBITDA to grow by just 5 percent in the December quarter.